Collateral damage from accelerated drug approval

Nature. 2023 Oct;622(7982):242. doi: 10.1038/d41586-023-03139-7.
No abstract available

Keywords: Medical research; Policy; Therapeutics.

Publication types

  • Letter

MeSH terms

  • Acceleration*
  • Drug Approval* / legislation & jurisprudence
  • Humans
  • Japan
  • United States
  • United States Food and Drug Administration